IDH1 and glioma: IDH mutations are considered important in glioma genesis, determining a more favorable outcome and longer survival with mutated IDH, than patients with wild-type IDH; therefore, IDH-1 status can also be used as a clinical prognosis indicator [5,6,7,8].